Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atebimetinib · 1 trial · 8 indications
The OS of participants with atebimetinib in combination with mGnP versus GnP
| Arm | Type | Description |
|---|---|---|
| Atebimetinib + mGnP | EXPERIMENTAL | Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma |
| GnP | ACTIVE_COMPARATOR | Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma |
| Name | Type | Description |
|---|---|---|
| Atebimetinib | DRUG | Once daily oral tablets |
| GnP | DRUG | Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion |
| mGnP | DRUG | Biweekly intravenous infusions of chemotherapy (gemcitabine and nab-paclitaxel) |
Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment...
Top 20 of 67 competitors
Atebimetinib is an investigational small molecule being studied for the treatment of pancreatic cancer, specifically as a first-line treatment in patients with metastatic pancreatic adenocarcinoma, including pancreatic ductal adenocarcinoma (PDAC). It is currently in Phase 3 clinical development.
Atebimetinib is a kinase inhibitor, as indicated by its -tinib suffix. It is designed to target kinases involved in cancer cell signaling, though the specific kinase targets have not been disclosed. It is being evaluated in combination with gemcitabine and nab-paclitaxel (GnP) for pancreatic cancer.
Atebimetinib is being developed by Immuneering Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol IMRX. The company is conducting a Phase 3 clinical trial of Atebimetinib in metastatic pancreatic adenocarcinoma.
Atebimetinib is in Phase 3 clinical development. It is currently being studied in a randomized, active-controlled trial for first-line treatment of metastatic pancreatic adenocarcinoma. The drug is investigational and has not been approved by regulatory authorities.
Atebimetinib is being evaluated in a Phase 3 clinical trial with the identifier NCT07562152. This trial is recruiting participants with metastatic pancreatic adenocarcinoma and is being conducted in the United States and Australia. The study enrolls adults aged 18 years and older.
Atebimetinib is a distinct investigational drug developed by Immuneering Corporation. It is not known to be the same as any other marketed or investigational drug. Its mechanism as a kinase inhibitor differentiates it from other pancreatic cancer treatments, though it is being tested in combination with standard chemotherapy.